Epivir

HIV, Treatment Naive, HIV + 3 more
Treatment
3 FDA approvals
20 Active Studies for Epivir

What is Epivir

LamivudineThe Generic name of this drug
Treatment SummaryDDC (didanosine) is a medication used to treat HIV-1 and hepatitis B infections. It works by blocking the action of an enzyme called reverse transcriptase, which helps the virus replicate. It is a type of zalcitabine analog, where the 3' carbon in the pentose ring is replaced by a sulfur atom.
Epiviris the brand name
image of different drug pills on a surface
Epivir Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Epivir Affects PatientsLamivudine is a drug used to treat HIV and hepatitis B. It works by stopping the virus from making copies of itself. When it is activated in the body, lamivudine makes molecules that interfere with the virus’s DNA, making it impossible for it to reproduce. Since lamivudine molecules lack a certain kind of chemical bond, they cannot help the virus create a DNA chain, preventing it from making copies of itself.
How Epivir works in the bodyLamivudine stops viruses from reproducing by preventing them from making copies of their DNA. It works by entering the virus and being changed into an active form. This active form then binds to the virus' DNA and stops it from making more copies.

When to interrupt dosage

The prescribed measure of Epivir is contingent upon the determined condition. The dose fluctuates, according to the technique of delivery featured in the presented table.
Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

There are 20 known major drug interactions with Epivir.
Common Epivir Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Epivir Toxicity & Overdose RiskCommon side effects of taking this drug may include headache, nausea, feeling tired or unwell, nasal problems, diarrhea, and coughing.
image of a doctor in a lab doing drug, clinical research

Epivir Novel Uses: Which Conditions Have a Clinical Trial Featuring Epivir?

Currently, 125 active trials are investigating the potential of Epivir in the management of Chronic Hepatitis B.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting

Epivir Reviews: What are patients saying about Epivir?

5Patient Review
12/1/2015
Epivir for HIV
1Patient Review
9/12/2020
Epivir for HIV
It worked for the first few weeks. But then, the side effects started! Hand and foot cramps, back spasms. No sleep for almost 2 months (cat naps), extreme weight loss 18 lbs in 5 weeks. Vision changes, passing out, breathing problems - finally lactic acidosis. Almost deadly to me; no recovery in sight!!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about epivir

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Epivir?

"You may experience a headache, dizziness, nausea, diarrhea, trouble sleeping, cough, tired feeling, or runny or stuffy nose."

Answered by AI

What is Epivir used to treat?

"Lamivudine is a medication used to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older. Lamivudine is also used to treat hepatitis b infection."

Answered by AI

How much does Epivir cost?

"The retail price for 30, 150MG Tablets of Epivir is $249.22. With a SingleCare Epivir coupon, however, you can get 30, 300MG Tablets of generic Epivir for only $49.17."

Answered by AI

What is the generic name for Epivir?

"This drug is available as a generic drug and a brand-name drug. Lamivudine oral solution is used to treat HIV infection in children.

The oral tablet form of lamivudine is used to treat HIV infection and hepatitis b (HBV) infection. Lamivudine is also available in oral solution form, which is used to treat HIV infection in children. Lamivudine is available as a generic drug or under the brand name Epivir."

Answered by AI

Clinical Trials for Epivir

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Epivir clinical trials? We made a collection of clinical trials featuring Epivir, we think they might fit your search criteria.Go to Trials
Have you considered Epivir clinical trials? We made a collection of clinical trials featuring Epivir, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Epivir clinical trials? We made a collection of clinical trials featuring Epivir, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security